Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, E. K.
Right arrow Articles by Grimm, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, E. K.
Right arrow Articles by Grimm, E. A.

Annals of Surgical Oncology, Vol 5, Issue 4 342-349, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Cell cycle regulation of human pancreatic cancer by tamoxifen

E. K. Robinson, A. M. Grau, D. B. Evans, C. M. Smid, P. J. Chiao, J. L. Abbruzzese and E. A. Grimm
Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: Clinical trials have suggested a survival advantage for selected patients with metastatic pancreatic cancer treated with tamoxifen. We sought to identify the molecular mechanism by which tamoxifen inhibits human pancreatic cancer cell (HPCC) growth. METHODS: HPCCs were grown in tamoxifen and growth inhibition was determined by 3H-thymidine uptake and by the MTT assay; changes in cell viability were determined by cell counts. Cell cycle alterations were evaluated by FACS, and the induction of apoptosis was evaluated using the TUNEL assay. Total cellular RNA was isolated after tamoxifen treatment, and Northern blot analysis was performed for p21waf1. RESULTS: Tamoxifen inhibited HPCC growth as measured by inhibition of 3H-thymidine incorporation and by the MTT assay. However, there was no decrease in the total number of viable cells after 6 days of treatment with 10 microM of tamoxifen and no evident apoptosis, confirming the absence of a cytotoxic effect. Cell cycle analysis revealed cellular arrest in the G0/G1 phase, which correlated with p21waf1 mRNA upregulation in response to tamoxifen treatment. CONCLUSIONS: Tamoxifen inhibits HPCC growth by inducing G0/G1 arrest with an associated increase in p21waf1 mRNA expression. Tamoxifen is an effective inhibitor of HPCC growth in vitro and warrants further in vivo study.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
T. K S Ku and D. L Crowe
Coactivator-mediated estrogen response in human squamous cell carcinoma lines
J. Endocrinol., April 1, 2007; 193(1): 147 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
M. Shen, P. Boffetta, J. H. Olsen, A. Andersen, K. Hemminki, E. Pukkala, E. Tracey, D. H. Brewster, M. L. McBride, V. Pompe-Kirn, et al.
A Pooled Analysis of Second Primary Pancreatic Cancer
Am. J. Epidemiol., March 15, 2006; 163(6): 502 - 511.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-H. Tang and E. A. Grimm
Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines
J. Biol. Chem., January 2, 2004; 279(1): 288 - 298.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.